CD Bioparticles Presents Upconverting Nanoparticle Conjugation Services


CD Bioparticles launches a personalized service for conjugating upconverting nanoparticles using various types of upconverting nanoparticles to conjugate with antibodies.

New York, United States – September 29, 2021 – With years of experience in the pharmaceutical and life sciences industry, CD Bioparticles is now launching a personalized upconverting nanoparticle conjugation service using various types of upconverting nanoparticles to be conjugated with antibodies, as probes for precise molecular detection and imaging, particularly in the fluorescence lateral flow immunoassay. Due to the NIR excitation, autofluorescence in biological samples is completely eliminated and particles are detectable through tissues and even in whole blood.

Upconverting Nanoparticles (UCNP) offer several advantages over traditional tags such as fluorophores or conventional quantum dots, such as stable and bright emission and long emission life, resistant to photobleaching induced by l ‘oxidation, to net emissions, to reduce the possibilities of spectra overlap and to the conversion of long wavelength near infrared excitation radiation into shorter wavelength emissions, to produce low active imaging background, large anti-Stokes shift, eliminated autofluorescence as well as high optical light penetration depth. Keys to UCNPs technology include an affordable laser that is sufficient for excitation purposes allowing a simple readout system, NaYF4 nanoparticles doped with ytterbium (Yb) and erbium (Er) or thulium (Tm). ), and small upconverting nanoparticles (30-35 nm).

CD Bioparticles offers a personalized service for the immobilization of antibodies on the surface of the particles and the substrate, and is also experienced in the conjugation of antibodies with complete supports such as beads, macro-supports, silicon, gold nanoparticles. and antibody microarray printing technology. This new upconverting nanoparticle conjugation service comes in addition to the Antibody Immobilization offer, and includes a series of personalized services, such as the synthesis of upconverting nanoparticles on demand, the conjugation of your biomolecules to UCNPs, screening or antibody purification, concentration and custom buffer. for the conjugate. Each personalized conjugation is tested by an LFIA test with materials supplied by the customer.

“We are delighted to offer this service to our customers. What customers need to do is choose your target biomolecule, identify target sensitivity, particle size, emission wavelength and components, final conjugate concentration, and provide quality control materials ” , said Dr Jessica Waldorf, Scientific Director of the R&D Department, at CD Bioparticles. “With our technology, expertise and UCNP capabilities, this new personalized service allows our customers to have more choice and to conjugate with antibodies, as probes for precise molecular detection and imaging, especially in fluorescence lateral flow immunoassay. We are happy to offer such a service in our global markets to provide our customers with expertise and efficient customer service.

CD Bioparticles also offers a series of upconverting monodisperse fluorescent nanoparticles that are bright, photostable and very well suited for use in quantitative lateral flow (LF) assays. For more information on the Custom Upgrading Nanoparticle Conjugation service or to discuss your project, please visit CD Bioparticles at https://www.cd-bioparticles.com.

About CD Bioparticles

CD Bioparticles is one of the world’s leading manufacturers and suppliers of various nanoparticles, microparticles and their coatings for R&D and commercialization in a wide variety of application areas including in vitro diagnostics, biochemistry, cell analysis, cell separation and immunoassay. It also offers various personalized services, including chemical functionalization of the surface, fluorescent modification, immobilization of antibodies, conjugation of nucleic acids and oligos to meet customer specifications.

Media contact
Company Name: CD Bioparticles
Contact: Richard J. Gray
E-mail: Send an email
Telephone: 1-631-346-0027
Country: United States
Website: http://www.cd-bioparticles.com


Source link

Previous Medterra 2021 Review | Medical News Today
Next Energy Crunch fuels calls to rethink EU green shift design

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *